| temozolomide / Generic mfg. |
NCT00612638: Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas |
|
|
| Completed | 1 | 96 | US | Temodar, O6-BG, and Irinotecan, Temodar-Temozolomide, O6-Benzylguanine-O6-BG, Irinotecan-Camptosar-CPT 11 | Duke University, Keryx / AOI Pharmaceuticals, Inc., Pharmacia | Glioblastoma, Gliosarcoma | 01/07 | 07/08 | | |
NCT00612989: Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM |
|
|
| Completed | 1 | 42 | US | Temodar and O6-Benzylguanine, Temodar, Temozolomide, O6-BG, O6-Benzylguanine, NSC637037, Neulasta, Pegfilgrastim | Duke University, Schering-Plough, Keryx / AOI Pharmaceuticals, Inc. | Glioblastoma, Gliosarcoma | 08/07 | 07/08 | | |
NCT00612651: PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas |
|
|
| Completed | 1 | 37 | US | Temodar and SCH 66336, Temodar-Temozolomide, Farnesyl transferase inhibitor-SCH 66336 | Duke University, Schering-Plough | Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma | 01/09 | 06/11 | | |
NCT00610571: Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas |
|
|
| Completed | 1 | 62 | US | Oral Topotecan and Temodar, Temodar - Temozolomide, Topotecan - Hycamtin | Katy Peters, GlaxoSmithKline, Schering-Plough | Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma | 09/09 | 04/12 | | |
NCT00734864: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma |
|
|
| Withdrawn | 1 | 0 | US | enzyme-inducing anti-epileptic drugs | Annick Desjardins, Bristol-Myers Squibb | Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma | 06/10 | 06/12 | | |
NCT00960063: A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) |
|
|
| Terminated | 1 | 4 | NA | Temozolomide, Vincristine, Ifosfamide, Irinotecan, Robatumumab, Doxorubicin, Cyclophosphamide, Etoposide | Merck Sharp & Dohme LLC | Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor, Neuroblastoma | 12/10 | 12/10 | | |
| Completed | 1 | 17 | Europe | Sorafenib dose escalation | University Hospital, Geneva, Bayer | Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma | 12/11 | 03/12 | | |
NCT00629343: Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide |
|
|
| Unknown status | 1 | 28 | US | Azacitidine In Combination With Temozolomide | Columbia University, Schering-Plough, Celgene Corporation | Soft Tissue Sarcoma, Mesothelioma | 10/12 | 08/14 | | |
NCT00960492: Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma |
|
|
| Completed | 1 | 26 | US | XL184, temozolomide, Temodar®, Radiation Therapy | Exelixis | Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma | 11/12 | 10/13 | | |
NCT03139331: PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma |
|
|
| Completed | 1 | 16 | US | Pazopanib, Irinotecan, Temozolomide | University of California, San Francisco, UCSF Benioff Children's Hospital Oakland, Dana-Farber Cancer Institute, Alex's Lemonade Stand Foundation | Sarcoma, Refractory Sarcoma | 10/19 | 09/20 | | |
NCT02502708: Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors |
|
|
| Completed | 1 | 81 | US | Indoximod, 1-methyl-D-tryptophan, D-1MT, Temozolomide, Temodar, Methazolastone, Conformal Radiation, Cyclophosphamide, Etoposide | NewLink Genetics Corporation | Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor | 12/19 | 02/20 | | |
|
|
|
|
NCT05698524: A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma |
|
|
| Recruiting | 1 | 18 | US | PCI 24781, Abexinostat, Temozolomide, Temodar | University of Nebraska, Xynomic Pharmaceuticals, Inc. | Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma | 02/25 | 06/27 | | |
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors |
|
|
| Recruiting | 1 | 20 | US | VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ | Valent Technologies, LLC | Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma | 06/24 | 06/24 | | |
NCT01189643: Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor |
|
|
| Active, not recruiting | 1 | 15 | US | irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator | Memorial Sloan Kettering Cancer Center, Genentech, Inc. | Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT) | 08/24 | 08/24 | | |
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
|
|
| Recruiting | 1 | 240 | US | INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide | Inhibrx, Inc. | Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors | 12/25 | 07/26 | | |
